LINE-1 methylation in plasma DNA as a biomarker of activity of DNA methylation inhibitors in patients with solid tumors

Epigenetics

Volumn 4, Issue 3, 2009, Pages 176-184

  Aparicio, Ana ^a   North, Brittany ^a   Barske, Lindsey ^b   Wang, Xuemei ^a   Bollati, Valentina ^c   Weisenberger, Daniel ^d   Yoo, Christine ^e   Tannir, Nizar ^a   Horne, Erin ^a   Groshen, Susan ^d   Jones, Peter ^d   Yang, Allen ^e   Issa, Jean Pierre ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF MILAN   (Italy)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Biomarkers; Cancer; DNA methylation; LINE; MAGE A1; Plasma DNA; Repetitive elements

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; DNA; MELANOMA ANTIGEN 1;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CARCINOMA; CELL STRAIN HCT116; CHEEK MUCOSA; CLINICAL ARTICLE; COLON CARCINOMA; CONTROLLED STUDY; DNA METHYLATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY CANCER; LONG INTERSPERSED REPEAT; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PROMOTER REGION; PROSTATE CANCER; PYROSEQUENCING; SOLID TUMOR;

EID: 66449125866     PISSN: 15592294     EISSN: 15592308     Source Type: Journal    
DOI: 10.4161/epi.4.3.8694     Document Type: Article

References (30)

1. Gore SD, Baylin S, Sugar E, Carraway H, Miller CB, Carducci M, et al. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res 2006; 66:6361-9.
2. Daskalakis M, Nguyen TT, Nguyen C, Guldberg P, Kohler G, Wijermans P, et al. Demethylation of a hypermethylated p15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2′-deoxycytidine (decitabine) treatment 2002; 100:2957-64.
3. Issa JP, Garcia-Manero G, Giles FJ, Mannari R, Thomas D, Faderl S, et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies. Blood 2004; 103:1635-40.
4. Yang AS, Doshi KD, Choi SW, Mason JB, Mannari RK, Gharybian V, et al. DNA methylation changes after 5-aza-2′-deoxycytidine therapy in patients with leukemia. Cancer Res 2006; 66:5495-503.
5. Kantarjian H, Oki Y, Garcia-Manero G, Huang X, O'Brien S, Cortes J, et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 2007; 109:52-7.
6. Samlowski WE, Leachman SA, Wade M, Cassidy P, Porter-Gill P, Busby L, et al. Evaluation of a 7-day continuous intravenous infusion of decitabine: inhibition of promoter-specific and global genomic DNA methylation. J Clin Oncol 2005; 23:3897-905.
7. Appleton K, Mackay HJ, Judson I, Plumb JA, McCormick C, Strathdee G, et al. Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. J Clin Oncol 2007; 25:4603-9.
8. Siegmund KD, Laird PW. Analysis of complex methylation data. Methods 2002; 27:170-8.
9. Esteller M, Sanchez-Cespedes M, Rosell R, Sidransky D, Baylin SB, Herman JG. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients 1999; 59:67-70.
10. Hoque MO, Feng Q, Toure P, Dem A, Critchlow CW, Hawes SE, et al. Detection of aberrant methylation of four genes in plasma DNA for the detection of breast cancer. J Clin Oncol 2006; 24:4262-9.
11. Esteller M, Corn PG, Baylin SB, Herman JG. A gene hypermethylation profile of human cancer. Cancer Res 2001; 61:3225-9.
12. Yang AS, Estecio MR, Doshi K, Kondo Y, Tajara EH, Issa JP. A simple method for estimating global DNA methylation using bisulfite PCR of repetitive DNA elements. Nucleic Acids Res 2004; 32:38.
13. Aparicio A, Weber JS. Review of the clinical experience with 5-azacytidine and 5-aza-2′-deoxycytidine in solid tumors 2002; 3:627-33.
14. Widschwendter A, Muller HM, Fiegl H, Ivarsson L, Wiedemair A, Muller-Holzner E, et al. DNA methylation in serum and tumors of cervical cancer patients. Clin Cancer Res 2004; 10:565-71.
15. Hsiung DT, Marsit CJ, Houseman EA, Eddy K, Furniss CS, McClean MD, et al. Global DNA methylation level in whole blood as a biomarker in head and neck squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 2007; 16:108-14.
16. Chalitchagorn K, Shuangshoti S, Hourpai N, Kongruttanachok N, Tangkijvanich P, Thong-ngam D, et al. Distinctive pattern of LINE-1 methylation level in normal tissues and the association with carcinogenesis. Oncogene 2004; 23:8841-6.
17. Phokaew C, Kowudtitham S, Subbalekha K, Shuangshoti S, Mutirangura A. LINE-1 methylation patterns of different loci in normal and cancerous cells. Nucleic Acids Res 2008; 36:5704-12.
18. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, et al. Initial sequencing and analysis of the human genome. Nature 2001; 409:860-921.
19. Taback B, O'Day SJ, Hoon DS. Quantification of circulating DNA in the plasma and serum of cancer patients. Ann NY Acad Sci 2004; 1022:17-24.
20. Gahan PB, Swaminathan R. Circulating nucleic acids in plasma and serum. Recent developments. Ann NY Acad Sci 2008; 1137:1-6.
21. Umetani N, Hiramatsu S, Hoon DS. Higher amount of free circulating DNA in serum than in plasma is not mainly caused by contaminated extraneous DNA during separation. Ann N Y Acad Sci 2006; 1075:299-307.
22. Jen J, Wu L, Sidransky D. An overview on the isolation and analysis of circulating tumor DNA in plasma and serum. Ann N Y Acad Sci 2000; 906:8-12.
23. Page K, Powles T, Slade MJ, MT DEB, Walker RA, Coombes RC, et al. The importance of careful blood processing in isolation of cell-free DNA. Ann NY Acad Sci 2006; 1075:313-7.
24. Ehrlich M. DNA methylation in cancer: too much, but also too little. Oncogene 2002; 21:5400-13.
25. Estecio MR, Yan PS, Ibrahim AE, Tellez CS, Shen L, Huang TH, et al. High-throughput methylation profiling by MCA coupled to CpG island microarray. Genome Res 2007; 17:1529-36.
26. Florl AR, Lower R, Schmitz-Drager BJ, Schulz WA. DNA methylation and expression of LINE-1 and HERV-K provirus sequences in urothelial and renal cell carcinomas. Br J Cancer 1999; 80:1312-21.
27. Clark SJ, Harrison J, Paul CL, Frommer M. High sensitivity mapping of methylated cytosines. Nucleic Acids Res 1994; 22:2990-7.
28. Gonzalgo ML, Jones PA. Rapid quantitation of methylation differences at specific sites using methylation-sensitive single nucleotide primer extension (Ms-SNuPE) 1997; 25:2529-31.
29. Yang AS, Estecio MR, Garcia-Manero G, Kantarjian HM, Issa JP. Comment on "Chromosomal instability and tumors promoted by DNA hypomethylation" and "Induction of tumors in nice by genomic hypomethylation". 2003; 302:1153.
30. Barske LBV, Yang AS, Aparicio AM. A comparison of bisulfite-based DNA methylation assays for the measurement of DNA methylation changes induced by decitabine. AACR-NCI-EORTC International Conference Molecular Targets and Cancer Therapeutics: Discovery, Biology and Clinical Applications. Philadelphia 2005.